Skip to content

Author

P. Borchmann

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Ibrutinib and standard immunochemotherapy in younger, high-risk patients with diffuse large B-cell lymphoma: A phase II study of GLA.

Younger patients with high-risk diffuse large B-cell lymphoma (DLBCL) frequently have unfavourable outcomes. We conducted a prospective phase II study evaluating ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOEP+I) in patients aged 18-60 years with DLBCL and age-adjusted internat...

E. Shumilov, M. Ziepert, B. Friedrichs et al. · 0 citations
Open access Sep 2026

Association between CAR T-cell persistence and improved response to salvage radiotherapy in patients with DLBCL

Background and purpose While Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL), over half of patients relapse within 1 year with poor prognosis. Salvage radiotherapy (sRT) achieves high local response rates, but which subgroups benefit...

Jia-Qi Fan, N. Kutsch, J. Heger et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.